Risk Factors Update Summary
- Revenue increased from $246 million to $274 million in 2023.
- Net loss changed to net income of $17 million to $28 million.
- Our Entre Plus system is now available for purchase by the Department of Veterans Affairs off contract.
- Revenue from lymphedema products increased from $212.3 million to $241.7 million in 2022.
- Reclassification of independent contractor trainers could impact our financial condition and results of operations.
- Entre system generation changed to Entre Plus in March 2023.
- A decrease from approximately $33 million to $17 million in Medicare accounts receivable.
- AffloVest revenue decreased from $34.5 million to $32.7 million in 2022.
- Field staff increased from 262 to 287 employees in 2023.
- Patient preference study showed 93% preference for AffloVest over traditional vests.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1027838&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.